Journal
NEURON
Volume 93, Issue 6, Pages 1252-1274Publisher
CELL PRESS
DOI: 10.1016/j.neuron.2017.02.002
Keywords
-
Categories
Funding
- INSERM, EU-Fp7 (PAINCAGE) [HEALTH603191]
- European Research Council [ERC-2010-StG-260515, ERC-2014-PoC-640923]
- Fondation pour la Recherche Medicale [DRM20101220445, DPP20151033974]
- Human Frontiers Science Program [RGP0036/2014]
- Region Aquitaine, AgenceNationale de la Recherche (ANR Blanc NeuroNutriSens) [ANR-13-BSV4-0006]
- BRAIN [ANR-10-LABX-0043]
- ANR Blanc ORUPS [ANR-16-CE37-0010-01]
- Fondation Francophone pour la Recherche sur le Diabete
- Federation Francaise des Diabetiques (AFD)
- AstraZeneca
- Eli Lilly
- Merck Sharp Dohme (MSD)
- Novo Nordisk
- Sanofi
Ask authors/readers for more resources
The type-1 cannabinoid receptor (CB1) is the main effector of the endocannabinoid system (ECS), which is involved in most brain and body functions. In this Perspective, we provide evidence indicating that CB1 receptor functions are key determinants of bodily coordinated exostatic processes. First, we will introduce the concepts of endostasis and exostasis as compensation or accumulation for immediate or future energy needs and discuss how exostasis has been necessary for the survival of species during evolution. Then, we will argue how different specific biological functions of the CB1 receptor in the body converge to provide physiological exostatic processes. Finally, we will introduce the concept of proactive evolution-induced diseases (PEIDs), which helps explain the seeming paradox that an evolutionary-selected physiological function can become the cause of epidemic pathological conditions, such as obesity. We propose here a possible unifying theory of CB1 receptor functions that can be tested by future experimental studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available